84 related articles for article (PubMed ID: 20606096)
21. "Personalizing" therapy for non-small cell lung cancer.
D'Cunha J
Semin Thorac Cardiovasc Surg; 2010; 22(2):118-20. PubMed ID: 21092888
[TBL] [Abstract][Full Text] [Related]
22. The coming of age of molecular tumor profiling.
Antonoff MB; D'Cunha J
Semin Thorac Cardiovasc Surg; 2011; 23(1):8-9. PubMed ID: 21807290
[TBL] [Abstract][Full Text] [Related]
23. Personalized medicine in advanced non-small-cell lung cancer: reality or wishful thinking?
Janku F; Bird B
J Clin Oncol; 2008 Dec; 26(34):5651; author reply 5651-2. PubMed ID: 18936465
[No Abstract] [Full Text] [Related]
24. Circulating tumor cells: not all detected cells are bad and not all bad cells are detected.
Wicha MS; Hayes DF
J Clin Oncol; 2011 Apr; 29(12):1508-11. PubMed ID: 21422428
[No Abstract] [Full Text] [Related]
25. Second-line treatment of non-small cell lung cancer: big targets, small progress; small targets, big progress?
Hanna N
J Thorac Oncol; 2006 Nov; 1(9):927-8. PubMed ID: 17409973
[No Abstract] [Full Text] [Related]
26. [Second-line treatment of metastatic non-small cell lung carcinoma: What are the options today? What are the perspectives for tomorrow?].
Greillier L; Barlesi F
Rev Mal Respir; 2012 Jan; 29(1):4-6. PubMed ID: 22240212
[No Abstract] [Full Text] [Related]
27. Patient selection criteria and the FLEX Study.
Herbst RS; Hirsch FR
Lancet; 2009 May; 373(9674):1497-8. PubMed ID: 19410696
[No Abstract] [Full Text] [Related]
28. Individualized therapy for patients with non-small cell lung cancer: emerging trends and challenges.
Langer CJ
Crit Rev Oncol Hematol; 2012 Jul; 83(1):130-44. PubMed ID: 22280915
[TBL] [Abstract][Full Text] [Related]
29. miRNA expression and its clinical implications for the prevention and diagnosis of non-small-cell lung cancer.
Gao W; Xu J; Shu YQ
Expert Rev Respir Med; 2011 Oct; 5(5):699-709. PubMed ID: 21955239
[TBL] [Abstract][Full Text] [Related]
30. Discussion - clinical trials and combination therapies in lung cancer. Clinical trial design.
J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S176-8. PubMed ID: 18520307
[No Abstract] [Full Text] [Related]
31. Advanced non-small cell lung cancer (ANSCLC): new chemotherapy phase II studies and old faults.
Tummarello D; Graziano F
Lung Cancer; 1996 Nov; 15(3):375-6. PubMed ID: 8959682
[No Abstract] [Full Text] [Related]
32. Personalized therapy for non-small cell lung cancer: hype or clinical reality?
Wigle DA
Semin Thorac Cardiovasc Surg; 2011; 23(1):30-5. PubMed ID: 21807296
[No Abstract] [Full Text] [Related]
33. Second-line chemotherapy for non-small cell lung cancer.
Ruckdeschel JC
Chest; 2006 Apr; 129(4):840-2. PubMed ID: 16608927
[No Abstract] [Full Text] [Related]
34. Randomized phase II trials: misleading and unreliable.
Stewart DJ
J Clin Oncol; 2010 Nov; 28(31):e649-50; author reply e651-3. PubMed ID: 20855829
[No Abstract] [Full Text] [Related]
35. Chemotherapy and survival in non-small cell lung cancer. Three years later.
Buccheri G
Chest; 1994 Oct; 106(4):990-2. PubMed ID: 7924540
[No Abstract] [Full Text] [Related]
36. Personalized medicine in the treatment of advanced nonsmall cell lung cancer: step-by-step progress.
Gridelli C
Curr Opin Oncol; 2012 Mar; 24(2):115-6. PubMed ID: 22123236
[No Abstract] [Full Text] [Related]
37. Impact of genetic polymorphisms in DNA repair enzymes on drug resistance in lung cancer.
Clin Lung Cancer; 2004 Sep; 6(2):79-82. PubMed ID: 15476592
[No Abstract] [Full Text] [Related]
38. How to combine cytotoxic and cytostatic agents.
Gridelli C
Lung Cancer; 2002 Oct; 38(1):S39-40. PubMed ID: 12367813
[No Abstract] [Full Text] [Related]
39. Biomarker testing in non-small cell lung cancer: a clinician's perspective.
Bernicker E
Arch Pathol Lab Med; 2015 Apr; 139(4):448-50. PubMed ID: 25166873
[No Abstract] [Full Text] [Related]
40. Durvalumab boosts progression-free survival in NSCLC.
Gourd E
Lancet Oncol; 2018 Jan; 19(1):e11. PubMed ID: 29175147
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
